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The participation of BRCA1 (breast cancer 1) in DNA repair is well established, especially in mammary and ovarian
cells. Our purpose was to develop a new in vivo radio-sensitizing therapy for melanoma. We therefore investigated
the effect of downregulation of BRCA1 on irradiated melanoma cells using an anti-BRCA1 ribozyme. Our results
show that BRCA1 downregulation increased radio-sensitivity of the A375 cell line, suggesting that BRCA1 could act
as a caretaker in melanoma; however, as BRCA1 functions are not limited to maintaining genomic integrity but also
regulate transcription and the cell cycle, we conﬁrmed that the proliferative rate of BRCA1 downregulated clones
did not change. We also demonstrate that: (1) among the major pro-angiogenic genes, FGF-2 was not increased
before or after irradiation and vascular endothelial growth factor strongly inhibited after irradiation; (2) expression
of two important metalloproteinases, matrix metalloproteinase 2 and 9, involved in melanoma metastasis were
decreased before and after irradiation; (3) expression of their major inhibitor, tissue inhibitor of metalloproteinase,
was mainly upregulated; and (4) that invasion of BRCA1 downregulated cells was modiﬁed. Together these data
suggest that BRCA1 downregulation in melanoma cells did not make them more aggressive and could lead to new
therapeutic strategies for this tumor, which is so difﬁcult to control once metastasized.
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Melanoma represents 10% of skin malignancies but
accounts for 80% of skin cancer deaths. The incidence of
melanoma is increasing in Caucasians at a rate of
approximately 5% per year, which is higher than for any
other solid tumor except lung cancer in women (Koh, 1991).
For primary cutaneous melanoma, surgery remains the
most effective treatment. Despite chemotherapy and inter-
feron immunotherapy (Lejeune, 1999; McMasters et al,
1999), the poor prognosis for a primary tumor with lymph
node and/or distant metastasis is the same as it was 30 y
ago.
Most agents used to treat melanoma are DNA-damaging
agents, such as alkylants, radiomimetics, and ionizing
radiation. The percentage of remission obtained with
radiation treatment, however, is statistically below that
obtained with surgery and chemotherapy, suggesting high
intrinsic radio-resistance of melanoma cells, which may be
due to an exceptional DNA repair capacity leading to
increased cell survival.
BRCA1 is a tumor suppressor gene mutated in 50% of
hereditary breast cancer cases and 80% of families
predisposed to breast and ovarian cancer (Castilla et al,
1994; Rahman and Stratton, 1998). BRCA1 is a cell cycle
regulated nuclear phospho-protein with transcription factor
activity, and there is evidence consistent with a role in DNA
damage repair. First, BRCA1 localizes in nuclear foci during
S phase and is rapidly dispersed when cells are treated by
DNA-damaging agents (Scully et al, 1997a). Secondly,
BRCA1 is hyperphosphorylated, mainly by ATM (mutated
in ataxia telangiectasia), in response to DNA damage (Gatei
et al, 2000). BRCA1 is also implicated in transcription-
coupled repair (Abbott et al, 1999), and by its interaction
with the RAD50/MRE11/Nibrin complex it is involved in
double-strand break repair through both homologous
recombination and nonhomologous end-joining (Zhong
et al, 1999; Zheng et al, 2000). As a part of BASC (BRCA1-
associated genome surveillance complex), BRCA1 could be
a detector of abnormal DNA structures (Wang et al, 2000).
Finally, Abbott et al (1999) demonstrated that in BRCA1 –/–
HCC1937 cells, hypersensitivity to irradiation can be
reversed by the expression of the wild-type form of BRCA1
that is not growth suppressive.
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Considering the putative role played by BRCA1 on DNA
damage repair, we investigated the effect of BRCA1
downregulation on melanoma cells under irradiation. We
transfected the A375 melanoma cell line with an anti-
BRCA1 ribozyme. We demonstrated that the downregula-
tion of BRCA1 increased radio-sensitivity and that this
downregulation did not enhance cellular proliferation. More-
over, it inhibits the expression of matrix metalloprotein-
ases MMP2 and MMP9, downregulates THromBoSpondine
(THBS) 1 protein expression without modifying those of
THBS2, inhibits vascular endothelial growth factor (VEGF)
expression at protein level, and does not influence fibroblast
growth factor (FGF)-2 mRNA and protein expression. At
last, invasion level of BRCA1 downregulated cells was
decreased and seems to be correlated with MMP2 protein
expression. Together these in vitro data suggest that
BRCA1 downregulation in melanoma cells did not make
them more aggressive.
Results
BRCA1 downregulation We obtained two rbz30-trans-
fected clones, c8.8 and c9.1, exhibiting rbz30 RNA expres-
sion (Fig 1) and showing 2 wk after transfection residual
BRCA1 expression of 67.4  17.9% (po0.002) and
49.3  15% (po0.002) respectively, as determined by
quantitative reverse transcription–PCR with BRCA1 30
primers (Fig 2a). To check whether this residual expression
was overestimated, as residual cleaved mRNA might be
amplified, we used the BRCA1 30R primers that flank
the cleavage site for another reverse transcription–PCR.
Expression was respectively 67.8  20.9 (po0.002) and
44.6  16.4 (po0.002), confirming that not all the BRCA1
mRNA was cleaved by the rbz30. A 110 kDa doublet bands
was observed, which is the phosphorylated and non-
phosphorylated 110 kDa BRCA1 protein form (Wilson
et al, 1999). Strong decrease of the 110 kDa doublet
was detected in c9.1 and c8.8. Moreover, a recovery of
BRCA1 mRNA and protein expression was observed
when these clones were cultured for an additional 4 mo
(Fig 2a,b).
Radio-sensitivity Clonogenic survival assays were per-
formed to test c8.8 and c9.1 viability after irradiation (Fig 3).
Irradiation with 1 Gy did not lead to significant viability
changes. Irradiation with 3 Gy revealed c8.8 and c9.1 to be
1.57-fold more radiosensitive compared with A375LXSN
(respectively p¼0.024 and p¼ 0.041). With 5 Gy, these
values were, respectively, 2.75 and 3.5 (p¼0.04 and
p¼0.027). When this experiment was proceeded on c9.1
and c8.8 cultured 4 mo prior irradiation, we did not
observed any difference in radio-sensitivity between the
Figure 1
Rbz30-RNA expression. Rbz30-RNA expression in parental A375 cells
(A375), a clone transfected with LXSN (A375LXSN) as negative control
and A375 clones transfected with LXSN-rbz30 was checked by
nonquantitative reverse transcription–PCR. Amplification generates a
350 bp fragment and was performed using VLXF and RBVXR primers.
Amplification without cDNA was performed as a negative control (T–).
Figure 2
BRCA1 expression in A375, A375LXSN, c8.1, and c9.1. (a) BRCA1
mRNA expression in A375LXSN, c9.1, and c8.8 were determined by
real-time quantitative PCR. At least, Three RNA extractions and three
reverse transcriptions were performed for each clone. Data are
expressed as percentages of the level in A375. Values represent
mean  SD. Significant differences between A375 and c9.1 or c8.8
were identified by po0.05. (b) BRCA1 protein expression: 35 mg of
total proteins were loaded and separated on 5% SDS–PAGE and
transferred to ImmobilonP membrane (Millipore). Immunostaining was
performed using 1/200 diluted anti-BRCA1 K18 (Santa-Cruz Biotech-
nology) or 1/5000 diluted anti-actin A4700 (Sigma). S: c8.8 and c9.1
clones cultured 4 mo after transfection.
Figure 3
Clonogenic survival assay. A375L
XSN, c8.8, and c9.1 cells were irradiated
with 1, 3, or 5 Gy. Results are mean  SD
of three experiments. Significant differ-
ences were observed between A375LXSN
and c8.8 or c9.1 (c8.8 or c9.1 vs
A375LXSN: po0.02; po0.046). S:
c8.8 and c9.1 clones cultured 4 mo after
transfection.
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two clones and A375LXSN (Fig 3). No significant difference
was observed between A375 and A375LXSN cells (1 Gy:
p¼0.48; 3 Gy: p¼0.18; 5 Gy: p¼ 0.21).
Quantiﬁcation of proliferation To assess whether BRCA1
downregulation changed cellular proliferation, c8.8 and c9.1
growth assays were performed over 216 h (Fig 4). Proli-
feration of the rbz30-transfected clones was not increased.
The only significant change in growth rate was observed for
c8.8, where a decrease was observed 168 h after plating
(p¼ 0.046).
SYBRGreen quantitative reverse transcription–PCR We
chose SYBRGreen technology to quantify gene expression.
As both specific and nonspecific PCR products would be
detected, to ensure amplification specificity we confirmed
that each SYBRGreen amplification generated only one
product, of the expected size (Fig 5, Table II).
Expression of THBS1, THBS2, VEGF, and FGF-2 The
expression of two potent inhibitors of melanoma angiogen-
esis, THBS1 and THBS2 (Detmar, 1996; Hawighorst et al,
2001) under 3 Gy irradiation was measured (Fig 6). Basal
THBS1 mRNA expression was increased 2.69-fold in c9.1
(269  32%; p¼ 0.02). At T2, no difference was observed
between c9.1 and A375LXSN, whereas at T4, expression in
c9.1 was significantly suppressed (67  8%, p¼0.030).
THBS1 expression was induced by irradiation in A375LXSN
at T2 (324  42%, p¼0.0169). This induction decreased
from T2 (324  42%) to T4 (165  28%, p¼ 0.015). THBS1
was also increased in c9.1 at T2 (374  60%), decreasing to
67  8% by T4 (p¼0.020). No significant difference was
found between T0 and T2 due to the increased basal
expression (Fig 6a). Expression of THBS2 mRNA in c9.1
was not significantly different from those in A375LXSN at
any time point (Fig 6c). In addition, no significant difference
was found between T0 and T2. THBS1 and 2 mRNA
expression in c8.8 was not induced by irradiation as it has
been observed in c9.1 and remained unchanged from T0 to
T4 (Fig 6b,d). Significant difference was observed for THBS
between c8.8 and control cells at T2 (THBS1: p¼ 0.045 and
THBS2: p¼ 0.023). THBS1 proteins expression level was
low at T0 and T2 in A375LXSN and increased at T4.
Expression in c8.8 and c9.1 was similar at T0, T2, and then
suppressed at T4 (Fig 7). At last, THBS2 protein expression
was expressed at the same level from T0 to T4 in the two
clones and control (Fig 7). As VEGF, and FGF-2 are known
to stimulate angiogenesis in melanoma (Graeven et al,
2001), we also checked their expression after irradiation (Fig
6). No significant difference was observed for VEGF mRNA
expression between c9.1 or c8.8 and A375LXSN at any time
point (Fig 6e,f) excepted at T2 where a significant
decreased was observed in c8.8 (p¼ 0.029, Fig 6f). No
significant difference was observed for VEGF protein
expression in c8.8, c9.1, and control cells at T0. Whereas
mRNA expression was not significantly changed, however,
VEGF protein was overexpressed in c8.8 and c9.1 at T2 and
suppressed at T4 (Fig 7). FGF-2 mRNA expression (Fig 6g,h)
Figure 4
Proliferation assay. Quantification of proliferation was performed using the SRB proliferation test. Three experiments using A375 parental cells,
A375LXSN, c8.8, and c9.1 were carried out to 264 h (c8.8 vs A375: p¼0.046).
Figure 5
SYBRGreen specificity. Amplification specificity was checked, load-
ing PCR products on a 2% agarose gel. Only one product with the
excepted size was obtained.
Table I. Primers and probes for real-time quantiﬁcation using Taqman
Gene Forward primer (50–30) Reverse primer (50–30) Taqman probe
BRCA130 CAGAGGACAATGGCTTCCATG CTACACTGTCCAACACCCACTCTC AATTGGGCAGATGTGTGAGGCACCTG
BRCA130R AGGAATTGCGGGAGGAAAA TGGTGGTTTCTTCCATTGACC TGAATGAGCATGATTTTGAAGTCAGAGGAGATG
18S CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT TGCTGGCACCAGACTTGCCCTC
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was induced by irradiation in c8.8, c9.1, and A375LXSN
(A375LXSN T0–T4: p¼ 0.033, c8.8 T2–T4: p¼0.02, c9.1
T0–T4, p¼0.01). Increase of FGF-2 (24 kDa isoform)
expression was observed in control after irradiation,
whereas no induction was observed in c8.8 and c9.1 from
T0 to T4 (Fig 7).
Expression of MMP1, MMP2, and MMP9 MMP1 mRNA
expression in c8.8 and c9.1 was not significantly different
from A375LXSN (Fig 8a,b). No significant variation of MMP1
protein expression was observed at T0, T2, and T4 (Fig 9).
MMP2 mRNA expression (Fig 8c,d), increased after irradia-
tion only in control cells, whereas it was initially over-
expressed in c9.1 (310  43%) but not in c8.8 (153  50%).
MMP2 expression was suppressed in c9.1 after irradiation
(84  17%, p¼0.03), whereas expression in c8.8 was
similar from T0 to T2 and slightly increased at T4
(188  40%). Gel zymography showed, that Pro-MMP2
expression was suppressed in c9.1 cells, 4.6-, 3.2-, and
2.0-fold at T0, T2, and T4 respectively. This feature is not
observed in c8.8 except at T2 where a 1.6-fold decreased
was observed (Fig 10). Basal MMP9 mRNA expression (Fig
8e,f ) was suppressed in c9.1 (17  7%; p¼0.037) and at a
lower extent in c8.8, and was induced by irradiation at T2
and T4 in c8.8, c9.1, and control cells. Gel zymography
showed, that MMP9 protein expression was suppressed in
c8.8 and c9.1 (Fig 10).
Expression of KiSS1 and TIMP1 KiSS1 was upregulated
4.1-fold at T0 in c9.1 (p¼0.01) but not in c8.8 (35  19%).
No significant difference was detected at T2 or T4 for both
rbz30-clones and A375LXSN (Fig 8g,h). TIMP1 mRNA was
expressed at the same level from T0 to T4 in A375LXSN. It
was overexpressed 3.0- and 2.2-fold in c9.1 at T0
(p¼ 0.041) and T2 (p¼0.0032) respectively, then decreased
to the level of A375LXSN at T4 (Fig 8i ). TIMP1 mRNA
expression in c8.8 was also overexpressed 5.45- and 4.2-
fold at T0 (p¼ 0.14) and T2 (p¼0.045), respectively,
whereas it was still overexpressed at T4 (p¼0.045, Fig
8j ). Reverse zymography, showed that TIMP1 activity was
similarly increased in c9.1 and c8.8 at each time point (Fig
10, c9.1: 1.9-, 1.52-, and 1.72-fold at T0, T2, and T4,
respectively, and c8.8: 2.4-, 2.7-, and 1.3-fold at T0, T2, and
T4, respectively).
In vitro invasion assays Next, we examined whether the
modulation of MMP2, MMP9, and TIMP1 expression was
associated with the ability of c8.8 and c9.1 to invade a filter
coated with Matrigel Matrix. As shown in Fig 11 c9.1
exhibited a strong decreased invasion as compared with
A375LXSN, whereas no significant decrease was observed
for c8.8.
Discussion
One major obstacle to the management of melanoma is its
intrinsic resistance to radiation therapy. Consequently, most
patients with melanoma do not respond to irradiation in a
clinically significant manner. Our purpose was to develop
new in vivo radio-sensitizing therapy for melanoma. We
therefore investigated the effect of downregulation of
BRCA1 on irradiated melanoma cells. BRCA1 participates
directly in DNA double-strand break repair through its
interactions with RAD51 and the RAD50/MRE11/Nibrin
complex (Scully et al, 1997b; Zhong et al, 1999). Further-
more, phosphorylation of BRCA1 upon DNA damage
implies a role for this protein in DNA damage-induced
signal relay (Cortez et al, 1999). BRCA1 may also co-
ordinate cell cycle progress with DNA repair (Zheng et al,
2000). All these data make BRCA1 a good target to obtain
radio-sensitizing treatments.
BRCA1 downregulation was obtained by transfecting
A375 melanoma cells with a ribozyme (rbz30), which
hybridizes to and cleaves the BRCA1 mRNA at the 30 end.
Rbz30 had strong and specific catalytic activity in vitro and
after transfection into HBL100 cells (Lafarge et al, 2001).
With A375, we obtained two clones with downregulated
BRCA1, c9.1 and c8.8 (Fig 2). Interestingly for both clones,
BRCA1 protein seemed to be more reduced than the
mRNA. Despite the lesser sensitivity of western blots
compared with quantitative reverse transcription–PCR,
these results suggested that rbz30 inhibited BRCA1 expres-
sion not only by mRNA cleavage but also by interfering with
translation. Clonogenic survival assays showed that radio-
sensitivity was significantly increased in these two clones.
This result is consistent with those obtained by Abbott et al,
1999), Zheng et al (2000) and Deng (2001) who respectively
showed that BRCA1-deficient HCC1937 cells, human cells
Table II. Primers and probes for real-time quantiﬁcation using SYBRGreen
Gene Forward primer (50–30) Reverse primer (50–30) Size (bp)
THBS1 CATCAGTGAGACCGATTTCCG GATGGCGTACAACCCAGTTAGG 92
THBS2 CCACTGCATCAAGGATAACTGC GTCATCATCACAGGCATCGC 91
VEGF CCATGGCAGAAGGAGGAGG ATTGGATGGCACTAGCTGCG 82
FGF-2 GTGTGCTAACCGTACCTGGC CTGGTGATTTCCTTGACCGG 130
KISS1 AACTCACTGGTTTCTTGGCAGC CTAGAATTCCCCACAGAGGCC 92
TIMP1 TCCGGTTCGTCTACACCCC TGAGAAACTCCTCGCTGCG 81
MMP1 ACGAATTTGCCGACAGAGATG GCCAAAGGAGCTGTAGATGTCC 113
MMP2 CACTGCGGTTTTCTCGAATCC AGTCCGTCCTTACCGTCAAAGG 102
MMP9 ACCACCTCGAACTTTGACAGC AGGAATGATCTAAGCCCAGCG 115
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carrying mutations of BRCA1, and brca1-null mouse ES
cells were all characterized by radiation hypersensitivity.
Furthermore, increased radio-sensitivity in our clones
shows that BRCA1 acts as a ‘‘caretaker’’ gene in melanoma
cells. After 4 mo of culture, C8.8 and c9.1 recovered BRCA1
expression and radio-resistance. As rbz30 RNA was still
detectable in this two long time cultured clones (data not
shown), we assume that BRCA1 is overexpressed to
balance rbz30 effect.
As cutaneous melanoma is characterized by its high
capacity for invasion and metastasis, and BRCA1 is
involved in G1/S (Aprelikova et al, 1999) and G2/M check-
point control progress (Xu et al, 1999) our next goal was to
assess whether BRCA1 downregulation had an effect on
cell proliferation. Growth assays showed that proliferation
was not enhanced by BRCA1 downregulation (Fig 4). This
result is consistent with the idea that downregulation or
upregulation of BRCA1 affects the growth of mammary and
Figure 6
Expression of angiogenic gene.
THBS1, THBS2, VEGF, and FGF-2 ex-
pression in A375LXSN, c9.1, and c8.8
were determined by real-time quantita-
tive PCR using SYBRGreen and 18S as
parallel control. Three RNA extractions
and three reverse transcriptions were
performed for each clone and for each
time (T0: 2 h before 3 Gy irradiation, T2
and T4: 5 h and 29 h after irradiation).
Data are expressed as percentages of
the level in A375LXSN at T0. Values
represent mean  SD. Significant differ-
ences between A375LXSN and c9.1 or
c8.8 were identified by po0.05.
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ovarian cancer cells without any effect on other types of
cells. Indeed, Thompson et al (1995), showed that inhibition
of BRCA1 expression with anti-sense oligonucleotides
increased growth of normal and malignant mammary cells,
but had no effect on other cell types such as pigmented
retinal epithelial cells. Others showed that overexpression of
BRCA1 inhibits in vitro growth of breast and ovarian cancer
cell lines, but not colon or lung cancer or fibroblasts (Holt
et al, 1996).
BRCA1 is involved in transcriptional regulation, interact-
ing not only with RNA Pol II holoenzyme (Scully et al, 1997c;
Anderson et al, 1998), but also with transcription factors
such as p53 (Ouchi et al, 1998; Zhang et al, 1998), and in
chromatin remodeling (Hu et al, 1999). Therefore, BRCA1
downregulation may disturb expression of crucial genes
involved in the two main mechanisms that control cell
aggressiveness: angiogenesis and metastasis. We therefore
checked whether BRCA1 downregulation modified the
expression of genes involved in these two processes.
Angiogenesis is a complex process that involves extra-
cellular matrix remodeling, endothelial cell (EC) migration
and proliferation and functional maturation of new EC into
mature blood vessels. EC integrate pro-angiogenic and
anti-angiogenic signals through their surface receptors
(Senger et al, 1997). Vascular homeostasis is maintained
by a balance between angiogenesis activators and inhibi-
tors. Imbalance between these two groups in a cell
population can increase its potential to induce new vessel
growth. Many anti-angiogenic or pro-angiogenic factors
have been described in melanoma angiogenesis. THBS1
and 2 are among major physiologic inhibitors of this process
(Detmar, 1996; Hawighorst et al, 2001). THBS1 and 2
belong to a family of ‘‘matricellular’’ proteins that mediate
interactions between extracellular matrix molecules such as
collagen and at least 12 different EC receptors (Bornstein,
1995). Interaction of THBS1 with CD36 induces EC
apoptosis (Dawson et al, 1997). To our knowledge, the
influence of ionizing radiation on THBS mRNA expressions
has never been studied. Our data suggest that THBS
expression was induced at the mRNA but not protein level.
In addition, whereas THBS2 protein expression was not
changed at any time point, a transient THBS1 protein
induction was observed that could be sufficient to generate
an anti-angiogenic signal. VEGF and FGF-2 are angiogen-
esis activators (Velasco and Lange-Asschenfeldt, 2002). In
vivo, VEGF enhances microvascular permeability (Senger
et al, 1983) and angiogenesis (Connolly et al, 1989). In vitro
VEGF induces EC migration towards several extracellular
matrices, partly through upregulation of the angiogenesis
mediator ava3 receptors and the collagen receptors a1a1
and a2a2 on EC (Senger et al, 1996, 1997). Our data showed
in both clones that VEGF mRNA expression was not
significantly increased by BRCA1 downregulation nor by
irradiation. Expression of VEGF protein, however, was
dramatically suppressed 29 h after irradiation (T4). The
temporary induction of THBS1 and the inhibition of VEGF
lead us to think that both clones should be less aggressive
in vivo. The interactions between VEGF and BRCA1 have
been poorly studied. One work reported that, in MCF7 and
HCC1937 cells, the induction of VEGF expression by the
estrogen receptor was inhibited by BRCA1 in the presence
of estrogen (Kawai et al, 2002). This effect could not be
observed in our cells, which were cultured in medium
without estrogen. As this mechanism has never been
studied in melanoma cells, we cannot exclude that, as in
vivo, in the presence of estrogen the downregulation of
BRCA1 could promote overexpression of VEGF. FGF-2 is a
pro-angiogenic factor and its radio-protective activity has
been recently pointed out by Ader et al (2002). This gene is
frequently upregulated in tumor cells and is induced by
irradiation (Thornton et al, 1996; Gorski et al, 1999; Houchen
et al, 1999). Our results showed that the same level of FGF-
2 mRNA and protein expression was induced by irradiation
in c9.1 and c8.8; however, increase of the 24 kDa FGF-2
isoform expression, observed in control cells 29 h after
irradiation, was not detected in the two BRCA1 down-
regulated clones. These data suggested that a post-
transcriptional regulation could exist, that could be under
the influence of BRCA1 downregulation and/or irradiation.
This low FGF-2 response to irradiation in the two clones
could in part explain the radio-sensitization as, recently,
Ader et al (2002) suggested that in HeLa cells and CAPAN
A3 pancreatic cells, the overproduction of FGF-2 24 kDa
isoform induced radio-resistance by activation of DNA-PK,
which is mainly involved in NHEJ (nonhomologous end
joining). An impairment of the HR (homologous recombina-
tion), however, may be associated with the c8.8 and c9.1
radio-sensitivity according to Ader et al (2002), and
Moynahan et al (1999) who showed that cells deficient in
BRCA1 exhibited a decrease in HR of DNA DSB and
showed slightly increased nonhomologous integration. All
these data suggest that irradiation and BRCA1 down-
regulation are associated with modulation of different genes
involved in the angiogenesis. We showed that BRCA1
Figure 7
THBS1, THBS2, VEGF, and FGF-2 protein expression. Forty-five
micrograms of total proteins were loaded and separated on 5%
(THBS1) and 15% (VEGF and FGF-2) SDS–PAGE and transferred to
ImmobilonP membrane (Millipore). Immunostaining were performed
using 1/100 diluted anti-THBS H300, anti-VEGF C1, and anti-FGF-2
147 (Santa Cruz Biotechnology) or 1/5000 diluted anti-actin A4700
(Sigma).
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downregulation modifies the expression of VEGF and
THBS1. These data provide new insight on melanoma
angiogenesis. We cannot assess the consequences of
these changes on the behavior of BRCA1 downregulated
cells in vivo, however, and this needs further investigation.
Metastatic growth requires tumor cells to invade normal
tissues. To accomplish this, tumor cells secrete a family of
zinc-dependant endoproteinases known as matrix metallo-
proteinases (MMP). Twenty-three members of this family
have been identified. Three of these, MMP1, MMP2, and
MMP9 are known to be particularly involved in melanoma
cell invasion (Hofmann et al, 2000). Moreover, MMP2 is
involved in angiogenesis partly through its interaction with
ava3 on EC (Silletti et al, 2001). We showed that MMP2 and
MMP9 but not MMP1 expression were disrupted by BRCA1
downregulation before (MMP2 and MMP9) or after (MMP2)
irradiation. In addition, we observed a strong decrease of
pro-MMP9 in both clones at any time point. Pro-MMP2
expression was decreased in c9.1 before and after
irradiation, whereas its expression was only decreased at
T2 in c8.8. The relation between MMP2 expression and p53
has been established. Toschi et al (2000) showed that
transfer of wild-type p53 into p53-mutated human melano-
ma cells could downregulate MMP2 expression. In our
Figure 8
Expression of metastasis gene.
MMP1, MMP2, MMP9, TIMP1, and
KiSS1 expression in A375LXSN, c9.1,
and c8.8 were determined by real-time
quantitative PCR using SYBRGreen and
18S as parallel control. Three RNA
extractions and three reverse transcrip-
tions were performed for each clone and
for each time (T0: 2 h before 3 Gy
irradiation, T2 and T4: 5 h and 29 h after
irradiation). Data are expressed as per-
centages of the level in A375L
XSN at T0. Values represent mean 
SD. Significant differences between
A375LXSN and c9.1 or c8.8 were identi-
fied by po0.05.
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model, parental cells, control clone, c8.8 and c9.1 had a
nonmutated p53 gene (data not shown). MMP2 inhibition is
not due to irradiation-induced p53 overexpression, as it is
not observed in control cells. The physical interaction
between BRCA1 and p53 (Zhang et al, 1998) may explain
our observations. To our knowledge, this effect of BRCA1
downregulation on MMP2 and MMP9 expression has never
been reported, and offers new insight into BRCA1 biology.
The balance between MMP and their inhibitors is critical
in determining switching from noninvasive cells to invasive
ones. In this study we analyzed two MMP inhibitors: TIMP-1
and KiSS1. Expression of KiSS1 is reduced in metastases
and its overexpression attenuates the invasive/metastatic
phenotype of different cancers (Lee et al, 1996; Lee and
Welch, 1997). KiSS1 protein represses MMP9 expression
(Yan et al, 2001), which may explain how KiSS1 decreases
tumor invasivity. In nonirradiated c9.1 cells, we found that
KiSS1 was overexpressed and MMP9 was downregulated.
In addition, neither KiSS1 nor MMP9 expression was
modified by BRCA1 downregulation in nonirradiated c8.8
cells and in both irradiated clones. Our model is in
accordance with the known transcriptional interaction
between these two genes. TIMP-1 is widely distributed
and inhibits the activity of all MMP (Gomis-Ruth et al, 1997;
Meng et al, 1999). TIMP-1 can also inhibit tumor cell
invasion and metastasis when it was overexpressed in
tumor cells (Gomez et al, 1997). We observed basal
overexpression of TIMP1 mRNA and an increased of TIMP1
activity in both clones at each time point. To our knowledge
no data have been published concerning the relationships
between BRCA1 and TIMP1. As these finding suggest that
BRCA1 downregulation forces c8.8 and c9.1 cells to
establish a new balance between MMP2 and MMP9 and
their inhibitors KiSS1 and TIMP1, we next investigated
whether their invasive capacity was modified. Our results
demonstrated that invasiveness of c9.1 was strongly
decreased, whereas those of c8.8 was similar to control
cells. Whereas MMP9 was decreased in both clones at any
time points, however, MMP2 expression was not decreased
in unirradiated c8.8 cells (Fig 10), which may explain this
result. Moreover, active MMP2 was only observed in highly
invasive melanoma cell lines and was absent in noninvasive
or poorly invasive cells (Hofmann et al, 1999; Kurschat et al,
1999), which is consistent with our data.
Interactions between BRCA1 and angiogenesis mechan-
isms on the one hand, and with metalloproteinases and their
inhibitors on the other hand, have never been studied. Our
data, in showing that BRCA1 deficiency could disturb
invasiveness and these two major pathways involved in
melanoma aggressiveness and that it is associated with
radio-sensitization of melanoma cells opens up a new
perspective in melanoma metastasis therapy.
Materials and methods
Cell culture The achromic human melanoma cell line A375
(American Type Culture Collection (Manassas, VA) CRL 1619)
was maintained in McCoy’s Medium containing 10% fetal bovine
serum, 1% penicillin–streptomycin, with 5% CO2 at 371C.
Design, construction of ribozyme, and transfection. The de-
sign, construction, and in vitro validation of a ribozyme (rbz30) that
cleaves BRCA1 mRNA at position 5282 were previously reported
(Lafarge et al, 2001). Transfection of A375 with plasmide LXSN with
or without rbz30 was performed using Lipofectin (Life Technologies
Gibco-BRL, Gaithersburg, MD) according to the manufacturer’s
protocol. After 3 wk of selection with 1 mg Geneticin per mL,
individual colonies were isolated and expanded.
Quantiﬁcation of proliferation This was done at 24 h, 144 h, 168
h, and 216 h using the sulforhodamine B (SRB) proliferation test.
Cells were plated at 500 cells per well in 96-well plates. At each
time point, cells were fixed with 50% trichloracetic acid for 1 h at
41C then washed with water and stained with SRB (Sigma, St
Louis, MO). Cells were washed with 1% acetic acid and SRB was
solubilized with 10 mM Tris–HCl (Sigma). SRB was quantified using
a spectrophotometer at 530 nm. Background was measured at
640 nm and subtracted from the 530 nm value. All the determina-
tions (OD) were normalized to the 24 h value (OD24h), which is the
plating control.
Cell irradiation Radio-sensitivity was measured in a colony
forming assay. Cells sufficient to produce 100 to 200 colonies for
each dose were plated: 400, 600, 800, and 2000 cells for
respectively 0, 1, 3, and 5 Gy. Cells were allowed to settle for 12
h before irradiation. The media was changed, and the cells were
allowed 10 to 16 d to form colonies of at least 50 cells, at which
point they were stained and counted. All data were normalized to
the number of cells plated and then to the 0 Gy values.
RNA extraction and reverse transcription For BRCA1 expres-
sion analysis, cells were harvested 48 h after plating at a density of
2106 cells per 175 cm2 flask. For angiogenesis and metastasis
gene expression analysis, cells were plated in 175 cm2 flasks 48 h
before T0 (T0: 2 h before irradiation). Cells were harvested at T0, T2
(5 h after irradiation), and T4 (29 h after irradiation). Total RNA was
isolated in 1 mL of TRIZOL (Gibco BRL) according to the
manufacturer’s protocol. RNA samples were dissolved in diethyl-
pyrocarbonate-treated water and their concentrations determined
by A260 measurements. Three micrograms of total RNA were
treated with 3 units of DNaseI, (Amp Grade, Gibco BRL) and 1 mg
reverse transcribed using the First-Strand cDNA synthesis kit
(Pharmacia Biotech, Uppsala, Sweden) with random hexamers.
Quantitative reverse transcription–poymerase chain reaction
(reverse transcription–PCR; real-time PCR Taqman technolo-
gy). Probes and primers (Table I), for gene expression analysis
were designed using Primer Express (Applied PE Biosystems, Kiel,
Germany). 18S rRNA was used as a standard of gene expression
according to Applied Biosystems’ instructions.
BRCA1 expression BRCA1 expression in the rbz30-transfected
clones was studied in three reverse transcription reactions from at
least three RNA extractions. Two primers flanking a labeled probe
containing both a fluorescent reporter dye and a quencher dye
were designed for both BRCA1 and 18S genes. During the
extension phase, the Taq DNA polymerase degrades the probe,
Figure 9
MMP1 protein expression Forty-five micrograms of total proteins
were loaded and separated on 9% SDS–PAGE and transferred to
ImmobilonP membrane (Millipore). Immunostaining were performed
using 1/100 diluted anti-MMP1 3B6 (Santa Cruz Biotechnology) or
1/5000 diluted anti-actin A4700 (Sigma).
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leading to the emission of the reporter dye once separated from
the effect of the quencher dye. The emitted fluorescence is directly
proportional to the number of amplicons produced during each
cycle. The PE Applied Biosystems 77 Sequence Detector
discriminates different reporter dyes used for the test gene
(BRCA1) and the reference gene (18S). Amplification was
performed in 25 mL containing 12.5 mL of 2  MasterMix (Applied
Biosystems), 400 nM primers and probe for BRCA1 (50 nM for 18S)
and 50 ng of cDNA. Amplification: 501C, 2 min; 951C, 10 min and
40 cycles 951C, 15 s; 601C, 1 min.
Angiogenesis and metastasis gene expression Expression of
MMP1, 2, and 9; tissue inhibitor of metalloproteinase (TIMP)1;
KiSS1 (KiSS metastasis-suppressor, metastin); FGF-2; VEGF;
THBS1, and THBS2 was studied in A375LXSN and rbz30-
transfected clones both before and after irradiation. RNA was
Figure 10
Activity of MMP2, MMP9, and TIMP1.
Forty-eight hours before T0, cells were
plated in T175 cm2 flask at a density of
2.106 cells per flask. Medium was re-
place by serum-free medium 24 h before
T0 (2 h before irradiation), T2 (5 h after
irradiation), or T4 (29 h after irradiation).
Proteins of the conditioned medium (CM)
were quantified using Bradford assays.
(a) Gelatin zymography: equal protein
mass was loaded on to SDS–9% poly-
acrylamide gel electrophoresis. Pro-
MMP2 0.1 ng and Pro-MMP9 0.1 ng
were loaded on each gel as positives
controls. Pro-form and mature form of
MMP2 are indicated on the left. (b)
Zymography reverse: equal protein mass
was loaded on to SDS–15% polyacryla-
mide gel electrophoresis. Two hundred
nanograms of pro-MMP2 was added to
the gel. TIMP1 was loaded as the
positive control. Quantification of clear
(MMP1 and 2) or dark (TIMP1) bands
volumes was obtained with Bio-Capt
and Bio-1D software (Vilbert Lourmat,
Marne La Valle´e) and values are indi-
cated in graphs.
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extracted 2 h before irradiation (T0), 5 h and 29 h after 3 Gy (T2 and
T4), for three independent experiments. A 3 Gy dose was chosen
because it allowed us to have enough live cells for RNA extraction.
Each extraction was reverse transcribed once and used for
quantitative real-time reverse transcription–PCR with SYBRGreen
(Applied Biosystems). All values were normalized to A375LXSN T0.
SYBR Green intercalates between the bases of dsDNA, thus
reporting the quantity of dsDNA without an additional fluorescently
labeled probe. Amplification was performed as described for
BRCA1, except that 18S expression was measured in parallel
reactions. Specificity was controlled by checking amplification
curves and verifying the PCR product on 1.5% agarose gels.
Relative quantification of gene expression by Taqman or SYBR
Green technology was performed using the comparative CT
method (Fink et al, 1998). The cycle threshold CT is the number
of cycles needed to reach the fluorescence detection threshold
and depends on the number of cDNA templates at the start of the
PCR. This method subtracts the average 18S CT value (each PCR
is done in triplicate) from the average test gene CT value, giving the
DCT. The level of mRNA expression in rbz30-transfected clones was
then normalized to that of control cells, giving normalized
expression (N.E.):
N:E: ¼formula
where DDCT¼DCT rbz30-transfected clones – DCT control cells and
assuming that efficiency of the PCR reaction was close to 1.
Nonquantitative reverse transcription–PCR Amplification be-
tween the VLXF primer: 50-TCAAGAAGACGT-TGGG-30 in the LXSN
vector and RBVXR primer: 50-TTCGTCCTCACGGACTCA-30 in the
rbz30-catalytic core generates a 350 bp product. Amplification was
done for 5 min at 941C (30 s at 941C, 30 s at 521C and 15 s at
721C)  50 followed by 7 min at 721C.
Protein extraction Cells were treated with RIPA lysis buffer (50
mM Tris–HCl pH 7.4, 1% nonidet P-40, 0.25% Na-deoxycholate,
150 mM NaCl, 1 mM ethylenediamine tetraacetic acid, 1 mM
Na3Vo4, 1 mM NaF) with protease inhibitors tablets (complete,
mini, ethylenediamine tetraacetic acid-free) for 10 min on ice.
Lysates were centrifugated at 12,000  g for 5 min at 41C and
supernatants were collected. Electrophoresis buffer (50 mM Tris–
HCl pH 6.8, 5% b-mercaptoethanol, 2% sodium dodecyl sulfate
(SDS), 0.1% bromophenol blue, 10% glycerol) was added to the
appropriate volume of total protein and then eat at 951C for 5 min.
Western blotting analysis of BRCA1 Thirty-five micrograms of
total proteins were loaded and separated on 5% SDS–polyacry-
lamide gel electrophoresis (SDS–PAGE) and transferred to Im-
mobilonP membrane (Millipore, St. Quetin-en-Yvelines, France).
Immunostaining was performed using 1/200 diluted anti-BRCA1
K18 (Santa Cruz Biotechnology, Santa Cruz, CA) or 1/5000 diluted
anti-actin A4700 (Sigma). The secondary antibody was anti-rabbit
or anti-mouse IgG conjugated to horseradish peroxidase (Santa
Cruz Biotechnology) diluted 1/2000 for 1 h and detected with the
ECL chemiluminescent detection system (Amersham Pharmacia
Biotech, Uppsala, Sweden).
Western blotting analysis of THBS1/2, MMP1, VEGF, and
FGF-2 Forty-five micrograms of total proteins were loaded and
separated on 5, 9, and 15% SDS–PAGE and transferred to
ImmobilonP membrane (Millipore). Immunostaining were per-
formed using 1/100 diluted anti-THBS H300, anti-MMP1 3B6,
anti-VEGF C1, and anti-FGF-2 147 (Santa Cruz Biotechnology) or
1/5000 diluted anti-actin A4700 (Sigma). The secondary antibody
was anti-rabbit or anti-mouse IgG conjugated to horseradish
peroxidase (Santa Cruz Biotechnology) as described above.
Gelatin zymography and reverse zymography MMP2 and
MMP9 activities were detected and characterized by gelatin
zymography in which gelatin, at a final concentration of 1 mg per
mL, was copolymerized in an 9% SDS–polyacrylamide gel. Cells
(2  106) were plated in T175 cm2 flasks 48 h before T0. Twenty-
four hours before T0, T2, or T4 cells were washed twice with
phosphate-buffered saline and then cultivated in serum-free
medium. Conditioned medium (24 h without serum) collected from
T0, T2, and T4 were harvested, normalized to equal protein
concentration (Bradford quantification) and subjected to SDS–
PAGE under nonreducing conditions at 41C (20 mA per gel).
Following electrophoresis, the gel was washed twice with 2.5%
Triton X100 for 30 min to remove the SDS. After a brief rinse with
distilled water, the gel was incubated for 18 h at 371C in 50 mM
Tris–HCl, 200 mM NaCl, 5 mM CaCl2, and 0.02% (w/v) Brij-35, pH
7.6. The gel was then stained with 0.1% Coomassie Brilliant Blue
and destained. Areas of MMP activity were indicated by the
appearance of clear bands against a dark blue background. Pro-
MMP2 (PF037 Calbiochem, Darmstadt, Germany) and pro-MMP9
(PF038 Calbiochem) were loaded on each gel as positive controls.
Reverse zymography was performed as described above except
that 200 ng of pro-MMP2 was added to the gelatin 15% SDS
polyacrylamide gel. Zymography and reverse zymography values
were obtained after quantification of clear bands volumes with Bio-
Capt and Bio-1D software (Vilbert Lourmat, Marne La Valle´e).
In vitro invasion assays Invasion was assayed in modified
Boyden chambers (tissue culture treated, 6.5 mm diameter, 8 mm
pore, Transwell, Dutscher, Brumath, France). Briefly, McCoy’s
medium supplemented with 10% fetal bovine serum and 2%
bovine serum albumin was used as a chemoattractant. Cells
(5  104) were suspended in serum-free McCoy’s medium contain-
ing 0.2% bovine serum albumin and seeded on to membranes
coated with Matrigel (30 mg per cm2) (Sigma). After a 40 h
incubation period, cells were fixed with methanol and stained with
crystal violet for 15 min. Cells remaining on the upper face of the
membranes were scrapped and those on the lower face were
counted using an inverted microscope.
Statistical analyses The results are presented as mean  SD of
at least three independent experiments. They were analyzed using
the two-sided Student’s t test.
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Figure 11
In vitro invasion assays. Invasion was assayed in modified Boyden
chambers (tissue culture treated, 6.5 mm diameter, 8 mm pore,
Transwell, Dutscher, Brumath, France). Data are expressed as
percentages of the level in A375LXSN. Values represent mean  SD.
Significant differences between A375LXSN and c9.1 was identified by
po 0.05.
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